Watch Demo

Latvia Antihypertensive Industry Outlook 2022 - 2026

See how Latvia Antihypertensive performed compared to key markets such as Germany, Italy and Spain.

Key Market Indicators

Sales of antihypertensive medicine in Latvia are expected to reach $5.3 million by 2026, growing at an average annual rate of 1.9%. This is up from $4.84 million in 2021, when Latvia ranked 19th in the world for antihypertensive drug sales. Since 2006, Latvian demand for antihypertensive medicine has increased by an average of 4.4% per year. Denmark led the way in 2021, with sales of $4.84 million. Italy, Spain, and Australia placed second, third and fourth, respectively.

Latvia Antihypertensive Market Data and Forecasts

How much will Latvia Antihypertensive Market grow to 2026?

Forecast: Renin-Angiotensin System Medicine Sales in Latvia
Forecast: Antihypertensive Medicine Sales in Latvia
Forecast: Renin-Angiotensin System Medicine Sales in Latvia
Forecast: Antihypertensive Medicine Sales in Latvia
Forecast: Renin-Angiotensin System Medicine Sales in Latvia
More in Antihypertensive Industry for 2027

Improve your Knowledge with the latest Indicators and Trends